Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line

D. A. Bronzert, T. J. Triche, P. Gleason, Marc E Lippman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The mechanism by which pharmacological concentrations of estrogen can paradoxically inhibit the growth of human breast cancer is unknown. We have selected for a variant line of MCF-7 which may help to understand this process. The variant was selected by exposing MCF-7 cells to high-specific-activity 16α-[125I]iodoestradiol. These cells were viably frozen for two isotopic half-lives, defrosted once, then reexposed to 16α-[125I]iodoestradiol to allow maximal radiation damage mediated by isotope associated with binding sites. This cell line (I13) is one of 55 lines cloned from MCF-7 cells that survived this treatment. The growth response to estradiol of the I13 breast cancer cells grown in monolayer is normal for 4 to 6 days, and then the cell number plateaus as the cells appear to round up and detach. Concomitantly, a decrease in [3H]thymidine incorporation occurs. The cells cannot be rescued by removing estradiol from the medium. The inhibition is dose dependent and can be seen in concentrations of estradiol as low as 10-10 M. The I13 cells are also inhibited by antiestrogens. They have normal levels of estrogen receptors which bind to DNA cellulose with activation. Progesterone receptors are estrogen inducible, although the levels are one-third that of wild-type MCF-7 cells. The morphological changes determined by electron microscopy of estrogen-treated cells are typical of degenerative cells. To investigate the possibility that inhibitory factors are secreted into the medium by I13 cells, conditioned medium from estrogen-exposed I13 cells is added to normal MCF-7 and I13 cells. No decrease in [3H]thymidine incorporation compared to controls is observed. When the secreted proteins are labeled with [35S]methionine and analyzed by sodium dodecyl sulfate-acrylamide gels, no major differences are apparent in the I13 and MCF-7 cells. Thus, the source of the defect is still unknown. It remains to be seen if the growth-inhibitory effects of 17β-estradiol on this cell line are receptor mediated or related to specific gene products which can be identified.

Original languageEnglish
Pages (from-to)3942-3951
Number of pages10
JournalCancer Research
Volume44
Issue number9
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Estrogens
Breast Neoplasms
Cell Line
MCF-7 Cells
Estradiol
Thymidine
Growth
Estrogen Receptor Modulators
Acrylamide
Progesterone Receptors
Conditioned Culture Medium
Isotopes
Sodium Dodecyl Sulfate
Estrogen Receptors
Methionine
Electron Microscopy
Cell Count
Gels
Binding Sites
Pharmacology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bronzert, D. A., Triche, T. J., Gleason, P., & Lippman, M. E. (1984). Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line. Cancer Research, 44(9), 3942-3951.

Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line. / Bronzert, D. A.; Triche, T. J.; Gleason, P.; Lippman, Marc E.

In: Cancer Research, Vol. 44, No. 9, 01.01.1984, p. 3942-3951.

Research output: Contribution to journalArticle

Bronzert, DA, Triche, TJ, Gleason, P & Lippman, ME 1984, 'Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line', Cancer Research, vol. 44, no. 9, pp. 3942-3951.
Bronzert, D. A. ; Triche, T. J. ; Gleason, P. ; Lippman, Marc E. / Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line. In: Cancer Research. 1984 ; Vol. 44, No. 9. pp. 3942-3951.
@article{a4d7d0f4c0aa496e8ab423a21853e6d7,
title = "Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line",
abstract = "The mechanism by which pharmacological concentrations of estrogen can paradoxically inhibit the growth of human breast cancer is unknown. We have selected for a variant line of MCF-7 which may help to understand this process. The variant was selected by exposing MCF-7 cells to high-specific-activity 16α-[125I]iodoestradiol. These cells were viably frozen for two isotopic half-lives, defrosted once, then reexposed to 16α-[125I]iodoestradiol to allow maximal radiation damage mediated by isotope associated with binding sites. This cell line (I13) is one of 55 lines cloned from MCF-7 cells that survived this treatment. The growth response to estradiol of the I13 breast cancer cells grown in monolayer is normal for 4 to 6 days, and then the cell number plateaus as the cells appear to round up and detach. Concomitantly, a decrease in [3H]thymidine incorporation occurs. The cells cannot be rescued by removing estradiol from the medium. The inhibition is dose dependent and can be seen in concentrations of estradiol as low as 10-10 M. The I13 cells are also inhibited by antiestrogens. They have normal levels of estrogen receptors which bind to DNA cellulose with activation. Progesterone receptors are estrogen inducible, although the levels are one-third that of wild-type MCF-7 cells. The morphological changes determined by electron microscopy of estrogen-treated cells are typical of degenerative cells. To investigate the possibility that inhibitory factors are secreted into the medium by I13 cells, conditioned medium from estrogen-exposed I13 cells is added to normal MCF-7 and I13 cells. No decrease in [3H]thymidine incorporation compared to controls is observed. When the secreted proteins are labeled with [35S]methionine and analyzed by sodium dodecyl sulfate-acrylamide gels, no major differences are apparent in the I13 and MCF-7 cells. Thus, the source of the defect is still unknown. It remains to be seen if the growth-inhibitory effects of 17β-estradiol on this cell line are receptor mediated or related to specific gene products which can be identified.",
author = "Bronzert, {D. A.} and Triche, {T. J.} and P. Gleason and Lippman, {Marc E}",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "44",
pages = "3942--3951",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Isolation and characterization of an estrogen-inhibited variant derived from the MCF-7 breast cancer cell line

AU - Bronzert, D. A.

AU - Triche, T. J.

AU - Gleason, P.

AU - Lippman, Marc E

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The mechanism by which pharmacological concentrations of estrogen can paradoxically inhibit the growth of human breast cancer is unknown. We have selected for a variant line of MCF-7 which may help to understand this process. The variant was selected by exposing MCF-7 cells to high-specific-activity 16α-[125I]iodoestradiol. These cells were viably frozen for two isotopic half-lives, defrosted once, then reexposed to 16α-[125I]iodoestradiol to allow maximal radiation damage mediated by isotope associated with binding sites. This cell line (I13) is one of 55 lines cloned from MCF-7 cells that survived this treatment. The growth response to estradiol of the I13 breast cancer cells grown in monolayer is normal for 4 to 6 days, and then the cell number plateaus as the cells appear to round up and detach. Concomitantly, a decrease in [3H]thymidine incorporation occurs. The cells cannot be rescued by removing estradiol from the medium. The inhibition is dose dependent and can be seen in concentrations of estradiol as low as 10-10 M. The I13 cells are also inhibited by antiestrogens. They have normal levels of estrogen receptors which bind to DNA cellulose with activation. Progesterone receptors are estrogen inducible, although the levels are one-third that of wild-type MCF-7 cells. The morphological changes determined by electron microscopy of estrogen-treated cells are typical of degenerative cells. To investigate the possibility that inhibitory factors are secreted into the medium by I13 cells, conditioned medium from estrogen-exposed I13 cells is added to normal MCF-7 and I13 cells. No decrease in [3H]thymidine incorporation compared to controls is observed. When the secreted proteins are labeled with [35S]methionine and analyzed by sodium dodecyl sulfate-acrylamide gels, no major differences are apparent in the I13 and MCF-7 cells. Thus, the source of the defect is still unknown. It remains to be seen if the growth-inhibitory effects of 17β-estradiol on this cell line are receptor mediated or related to specific gene products which can be identified.

AB - The mechanism by which pharmacological concentrations of estrogen can paradoxically inhibit the growth of human breast cancer is unknown. We have selected for a variant line of MCF-7 which may help to understand this process. The variant was selected by exposing MCF-7 cells to high-specific-activity 16α-[125I]iodoestradiol. These cells were viably frozen for two isotopic half-lives, defrosted once, then reexposed to 16α-[125I]iodoestradiol to allow maximal radiation damage mediated by isotope associated with binding sites. This cell line (I13) is one of 55 lines cloned from MCF-7 cells that survived this treatment. The growth response to estradiol of the I13 breast cancer cells grown in monolayer is normal for 4 to 6 days, and then the cell number plateaus as the cells appear to round up and detach. Concomitantly, a decrease in [3H]thymidine incorporation occurs. The cells cannot be rescued by removing estradiol from the medium. The inhibition is dose dependent and can be seen in concentrations of estradiol as low as 10-10 M. The I13 cells are also inhibited by antiestrogens. They have normal levels of estrogen receptors which bind to DNA cellulose with activation. Progesterone receptors are estrogen inducible, although the levels are one-third that of wild-type MCF-7 cells. The morphological changes determined by electron microscopy of estrogen-treated cells are typical of degenerative cells. To investigate the possibility that inhibitory factors are secreted into the medium by I13 cells, conditioned medium from estrogen-exposed I13 cells is added to normal MCF-7 and I13 cells. No decrease in [3H]thymidine incorporation compared to controls is observed. When the secreted proteins are labeled with [35S]methionine and analyzed by sodium dodecyl sulfate-acrylamide gels, no major differences are apparent in the I13 and MCF-7 cells. Thus, the source of the defect is still unknown. It remains to be seen if the growth-inhibitory effects of 17β-estradiol on this cell line are receptor mediated or related to specific gene products which can be identified.

UR - http://www.scopus.com/inward/record.url?scp=0021146245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021146245&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 3942

EP - 3951

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -